It's all in the face: Amiodarone-induced myxedema and skin pigmentation [10]

European Journal of Dermatology

Volumn 16, Issue 5, 2006, Pages 590-591

  Raptis, Lampros ^a   Papathanasiou, Helias ^a   Pappas, Georgios ^b   Akritidis, Nikolaos ^a  

^a G HATZIKOSTA GENERAL HOSPITAL   (Greece)

^b Institute of Continuing Medical Education of Ioannina   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; LEVOTHYROXINE;

AGED; ANAMNESIS; CASE REPORT; CLINICAL FEATURE; DRUG WITHDRAWAL; FACE; FEMALE; HEART ATRIUM FIBRILLATION; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; LABORATORY TEST; LETTER; MICROSCOPY; MYXEDEMA; PUNCH BIOPSY; SIDE EFFECT; SKIN PIGMENTATION; THYROID FUNCTION TEST; TREATMENT OUTCOME;

AGED; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; FEMALE; HUMANS; HYPERPIGMENTATION; MYXEDEMA; THYROID DISEASES;

EID: 33845246654     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med 2005; 118: 706-14.
2. Hilleman D, Miller MA, Parker R, et al. Optimal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy 1998; 18: 138S-45S.
3. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev 2001; 22: 240-54.
4. Dootson G, Byatt C. Amiodarone-induced vasculitis and a review of the cutaneous side-effects of amiodarone. Clin Exp Dermatol 1994; 19: 422-4.
5. Waitzer S, Butany J, From L, et al. Cutaneous ultrastructural changes and photosensitivity associated with amiodarone therapy. J Am Acad Dermatol. 1987; 16: 779-87.
6. Tisdale JE, Follin SL, Ordelova A, Webb CR. Risk factors for the development of specific noncardiovascular adverse effects associated with amiodarone. J Clin Pharmacol. 1995; 35: 351-6.